Insider Selling: Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Sells 2,500 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry sold 2,500 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $7.52, for a total value of $18,800.00. Following the sale, the general counsel now directly owns 72,250 shares in the company, valued at approximately $543,320. The trade was a 3.34 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Benjamin Landry also recently made the following trade(s):

• On Friday, December 6th, Benjamin Landry sold 19,268 shares of Health Catalyst stock. The shares were sold at an average price of $8.32, for a total transaction of $160,309.76.

Health Catalyst Stock Performance

NASDAQ HCAT opened at $6.89 on Friday. Health Catalyst, Inc. has a 1-year low of $5.42 and a 1-year high of $11.41. The business’s 50-day simple moving average is $7.79 and its 200-day simple moving average is $7.53. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The firm has a market capitalization of $419.24 million, a P/E ratio of -5.10 and a beta of 1.36.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The business had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $76.27 million. During the same quarter in the prior year, the firm earned ($0.22) earnings per share. Health Catalyst’s quarterly revenue was up 3.5% compared to the same quarter last year. Equities analysts predict that Health Catalyst, Inc. will post -0.33 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on HCAT. Piper Sandler reissued an “overweight” rating and issued a $12.00 price objective (up previously from $11.00) on shares of Health Catalyst in a research report on Tuesday, November 26th. Citigroup decreased their price objective on Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a report on Friday. Stephens lifted their price objective on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research report on Thursday, November 14th. Royal Bank of Canada increased their target price on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Finally, Evercore ISI lifted their price target on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $11.45.

Institutional Trading of Health Catalyst

Large investors have recently added to or reduced their stakes in the stock. Primecap Management Co. CA boosted its position in shares of Health Catalyst by 14.7% in the second quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock worth $15,205,000 after buying an additional 305,079 shares during the period. Janney Montgomery Scott LLC acquired a new stake in Health Catalyst in the third quarter valued at approximately $897,000. Fred Alger Management LLC purchased a new stake in shares of Health Catalyst during the third quarter valued at approximately $6,858,000. Millrace Asset Group Inc. acquired a new position in shares of Health Catalyst during the third quarter worth $1,568,000. Finally, Point72 Asset Management L.P. boosted its stake in shares of Health Catalyst by 69.4% in the third quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock valued at $4,208,000 after purchasing an additional 211,805 shares during the period. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.